US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

Headquartered in Munich, Germany, the company aims to address unmet medical needs in ophthalmology through proprietary gene ...

Shares of Swedish drugmaker Camurus shot up 23% to 638.50 kronor yesterday on news of that it has entered a collaboration and license agreement with Eli Lilly, granting the US pharma major exclusive, ...

The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal ...

San Jose, USA-based biotech Allay Therapeutics today announced the completion of a $57.5 million Series D financing round ...

A sweeping legislative package backed by US President Donald Trump could strip health insurance from more than 16 million ...

German genetic medicine company ViGeneron has announced a rebrand to become VeonGen Therapeutics. The privately-held firm has ...

US rare disease meds developer Sarepta Therapeutics (Nasdaq: SRPT) revealed that its rAAVrh74 viral vector used in the ...

US biopharma Cullinan Therapeutics has entered into an agreement with Genrix Bio for an all-indication, exclusive license to ...

China’s National Medical Products Administration approved its first domestically-developed nine-valent human papillomavirus ...

The atopic dermatitis market across the seven major markets is forecast to nearly triple in value over the next decade, ...

The NHS Business Services Authority (NHSBSA) has published the annual Prescription Cost Analysis (PCA) for 2024/25.